Navigation Links
UPDATE: Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure
Date:10/11/2007

ve NPR-B agonist with potent renal enhancement and cardiac unloading properties, but with minimal hypotensive effects.

About Heart Failure

Heart failure is a chronic condition in which the heart cannot effectively pump enough blood to the body's other organs. Heart failure is the fastest- growing clinical cardiac disease in the United States, affecting 5 million Americans. In the U.S., more than $30 billion is spent each year to treat heart failure. Approximately 1 million patients in the U.S. each year are hospitalized with acute decompensated heart failure (ADHF). These ADHF patients face high rates of morbidly and mortally following hospital discharge, with 6-month hospital re-admission and mortality rates of 50% and 33%, respectively.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric peptide in Phase I studies for the treatment of heart failure, and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties. A key component of the Company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

Contact:

Daron Evans

Chief Financial Officer

Nile Therapeutics, Inc.

510-281-7700

info@nilethera.com

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strate
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015  Holographic Optical Technologies of ... holographic medical imaging, is entering the world of consumer ... on April 20 th , 2015, the campaign will ... 8-inch and 22-inch displays will allow consumers to view ... time. In addition to the two displays, the company ...
(Date:3/27/2015)... DIEGO , March 27, 2015   ... company, today announced new data showing that, compared ... TM technology provided highly equivalent interpretations of ... disease, and did so in a fraction of ... the way for more comprehensive genetic analysis in ...
(Date:3/27/2015)... 2015 XRpro Sciences, Inc., a provider ... development services which features high throughput transporter and ... financial results for the year ended December 31, ... of XRpro Sciences commented, "We have completed a ... stage to commercial stage in large part by ...
Breaking Medicine Technology:Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4
... 2, 2011 Nile Therapeutics, Inc. (Nasdaq: ... novel therapeutics for heart failure patients, today announced that, ... determination from the NASDAQ Listing Qualifications Panel (the "Panel") ... for an extension to remain listed on The NASDAQ ...
... 2011 Pacira Pharmaceuticals, Inc., (Nasdaq: ... announced that positive results from its Phase 1 ... patients with moderate hepatic impairment, will be presented ... and Therapeutics (ASCPT) 112th Annual Meeting in Dallas, ...
Cached Medicine Technology:Nile Therapeutics Receives Positive NASDAQ Panel Decision 2Nile Therapeutics Receives Positive NASDAQ Panel Decision 3Pacira Pharmaceuticals' EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting 2Pacira Pharmaceuticals' EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting 3
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Pitching speed, ... a history of shoulder and elbow injuries, according to new ... Medicine’s ( AOSSM ) Specialty Day. , “Our findings indicate ... a 20% increase in likelihood of a history of injury, ... with a 12% increase likelihood of a history of injury, ...
(Date:3/28/2015)... 2015 Delaying rotator cuff surgery on ... to research presented today at the American Orthopaedic Society ... “Our study compared results for 170 patients who received ... glenohumeral joint capsule release procedure to relieve stiffness at ... lead author from St. George Hospital in Sydney, Australia. ...
(Date:3/28/2015)... 2015 Andrew Hawley of Vintage Rock Posters ... concert posters. The Who and the Doors played together at ... 1968. According to Hawley, “The Who toured the United States ... college campuses. Perhaps the most famous Who poster was a ... the Doors on August 2, 1968 at the Singer Bowl ...
(Date:3/28/2015)... La Mirada, CA (PRWEB) March 28, 2015 ... with ear, nose and throat disorders, are ... Tinnitus is a common issue which is characterized by ... ears. Affecting 1 in 5 people, tinnitus is a ... or disorder and while it is non-fatal, tinnitus can ...
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s Wellness Celebration ... Conference Center in Chesapeake, Virginia. Each year, ARDX celebrates ... in the Hampton Roads region. The 2015 Women’s History ... Women grow stronger through sharing their stories and learning the ... WWC™ theme is T-talk where we will share a cup ...
Breaking Medicine News(10 mins):Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2
... A new type of diagnostic imaging - which can ... cancerous - could be used to prevent unnecessary surgery ... A study by Belgian researchers, which will be ... Society,s Annual Congress in Amsterdam, found that the new ...
... in moderate quantities can reduce the risk of asthma, according ... today (25 September 2011) at the European Respiratory Society,s Annual ... a week could reduce the risk of developing the condition. ... of 12 and 41 yrs of age. All participants completed ...
... A major UK trial has produced firm evidence that ... with early breast cancer significantly reduces the risk of ... The treatment, known as synchronous chemoradiation, has minimal adverse ... of life. Findings from the SEquencing of ...
... of the care of patients with rectal cancer have ... chemotherapy and radiotherapy between European countries. The European ... the European CanCer Organisation compared the treatment ... Netherlands who were diagnosed with rectal cancer between 2008 ...
... for patients with bone metastases from advanced prostate cancer ... III study of an alpha-pharmaceutical in these patients has ... research reported today (Saturday) at the 2011 European Multidisciplinary ... Parker, Consultant Clinical Oncologist at the Royal Marsden Hospital, ...
... Sept. 23 (HealthDay News) -- People,s bodies build up vitamin ... black men who live in areas of the United States ... deficiency than whites who live in the same places. ... recommendations need to change. "This study shows that across-the-board vitamin ...
Cached Medicine News:Health News:New diagnostic imaging for lung cancer could prevent unnecessary surgery 2Health News:Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence 2Health News:Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence 3Health News:Treatment of rectal cancer varies enormously between different European countries 2Health News:Treatment of rectal cancer varies enormously between different European countries 3Health News:First Phase III trial of an alpha-pharmaceutical 2Health News:First Phase III trial of an alpha-pharmaceutical 3Health News:Many Black Men in Cold Climates Lack Vitamin D 2
... Volks Centralis Direct Laser Lens affords the ... posterior segment of the eye. Utilizing a ... bonded protective glass LaserWindow™ exterior, this special ... other lower profile fundus lenses. Available in ...
... Area Centralis® is excellent for critically ... changes from macular degeneration, retinal vascular ... retinopathy and other retinal conditions. It ... of these conditions providing excellent magnification ...
... The Volk TransEquator is designed for ... diagnosis. Its unique optical design presents a ... an impressive wide-field view of the entire ... superior optics of this lens allows dynamic ...
... This unique 129 diopter contact lens has ... at the slit lamp when traditional non-contact ... views. The Equator Plus delivers an outstanding ... be used with pupils as small as ...
Medicine Products: